Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alchemab Therapeutics

Request full access

Develops drugs by identifying naturally protective patient antibodies using three complementary processes and advanced technologies

London, United KingdomFounded 2019Biotech & Life Sciences

About Alchemab Therapeutics

Alchemab Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically in the development of antibody therapeutics for difficult-to-treat diseases. The company's unique approach involves studying the immune systems of resilient individuals, such as long-term cancer survivors, to understand how they resist or overcome disease.

The company's business model is centered around the use of adaptive immunity, which is the body's ability to recognize and defend itself against specific infectious agents or diseases. Alchemab uses advanced scientific techniques and deep learning algorithms to identify and replicate the antibodies present in these resilient individuals. These antibodies are then used to create therapeutics that can potentially treat a wide range of diseases.

Alchemab's clients are primarily in the healthcare sector, including hospitals, clinics, and other medical institutions that treat patients with hard-to-treat diseases. The company generates revenue by developing and selling these novel antibody therapeutics.

In summary, Alchemab is a pioneering biotech company that uses innovative techniques to develop new treatments for hard-to-treat diseases. By harnessing the power of the immune system and using advanced technology, the company is at the forefront of the next generation of antibody therapeutics.

Source: Dealroom company data

At a glance

Status
Operational
Employees
71
Open positions
None listed
Dealroom signal
92.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, AI Drug Discovery, Woman Founder, Techbio Drug Discovery, DT and LS, UKis Digital and technologies
Technology
Artificial Intelligence, Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Sep 2025 $32M $410M SV Health Investors · Eli Lilly · Lilly · DCVC Bio ↗
GRANTOther financing Jun 2024 $595K — Michael J. Fox Foundation for Parkinson's Research ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Alchemab Therapeutics website traffic

Latest recorded traffic for Alchemab Therapeutics is 4.6K monthly website visits, up 12.2% over the last three months. Alchemab Therapeutics's team grew 18.3% over the past year.

Latest monthly visits4.6K 3-month web change+12.2% 1-year team growth+18.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Alchemab Therapeutics in the London ecosystem

Live from Dealroom

The Alchemab Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • SV Health Investors
  • DCVC
  • Michael J. Fox Foundation for Parkinson's Research

Series A8 investors entered at this stage

  • RA Capital Management
  • Lightstone Ventures
  • DHVC (Danhua Capital)
  • Dementia Discovery Fund
  • Ono Venture Investment
  • Eli Lilly
  • Lilly
  • DCVC Bio
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Alchemab Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.